The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase II study of low-dose paclitaxel with timed thoracic radiotherapy (TTR) followed by gemcitabine and carboplatin consolidation in patients with unresectable stage III non-small cell lung cancer (NSCLC): NCT 00449657.
J. Zhang
No relevant relationships to disclose
S. M. Russo
No relevant relationships to disclose
H. A. Gay
No relevant relationships to disclose
T. Parent
No relevant relationships to disclose
Z. Nelson
No relevant relationships to disclose
S. Eubanks
No relevant relationships to disclose
P. R. Walker
No relevant relationships to disclose